
A short YouTube segment by Dr. Charles Mok describing plasmapheresis (plasma apheresis) as studied in the AMBAR trials for mild-to-moderate Alzheimer’s disease. The speaker summarizes the procedure (removing/discarding plasma to reduce tau and beta‑amyloid, replacing with saline and albumin), reports that trial participants showed clinical improvement, and notes the trials were not powered for FDA approval—so plasmapheresis is not FDA‑approved specifically for Alzheimer’s though the procedure itself is FDA‑approved for other indications. The speaker names clinician David Hassi at the Maxwell Clinic in Nashville, TN as someone who performs the treatment.
Questions this video answers
David Hassi at the Maxwell Clinic in Nashville, Tennessee.
The AMBAR trials.
Saline and albumin.
Mild-to-moderate Alzheimer's disease (including mild cognitive impairment).










